Αρχική World News ESMO Virtual Congress 2020, 19-21 September

ESMO Virtual Congress 2020, 19-21 September [ESMO Media Alert]

LUGANO, Switzerland – The ESMO Congress 2020 will be held as a virtual meeting, with the programme delivered over two weekends:

  • Science weekend on 19-21 September
  • Educational weekend on 16-18 October

ESMO welcomes media interested in reporting from the ESMO meetings and on cancer issues. Only through the official accreditation process with the ESMO Media Registration Form accredited media representatives will be able to access embargoed material and official press conferences.

The scientific programme will include the presentation of the latest cancer research results with more than 2100 abstracts, including around 100 expected late-breaking abstracts. Abstract titles are already listed in the online programme, the titles of accepted late-breaking abstracts will be made available at the end of August.

Please note the new embargo schedule for the ESMO Virtual Congress 2020:

  1. Abstracts accepted for presentation at the ESMO Virtual Congress 2020 as Poster (suffix ‘P’, ‘TiP’) and EONS Poster (prefix ‘CN’) will be published online via the ESMO website at 00:05 CEST on Monday, 14 September 2020.
  2. Abstracts and late-breaking abstracts accepted for presentation at the ESMO Virtual Congress 2020 as Mini Oral (suffix ‘MO’) will be published online via the ESMO website at 00:05 CEST on Friday, 18 September 2020.
  3. Abstracts and late-breaking abstracts accepted for presentation at the ESMO Virtual Congress 2020 as Proffered Paper (suffix ‘O’) and EONS Proffered Paper (prefix ‘CN’) will be published online via the ESMO website at 00:05 CEST on Saturday, 19 September 2020.
  4. Abstracts and late-breaking abstracts selected for inclusion in the ESMO Press Programme will be published online according to a dedicated schedule which will be made available by early September.
  • Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.
  • Data and information beyond what is included in all accepted abstracts, including full data sets and full manuscripts, may only be made public at the start of the official programme session during which the study is presented.

Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO meetings.

Further information

ESMO Press Office

media@esmo.org

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer, Breast Cancer, and Sarcoma

In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field...

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

The right combination for early detection

The upcoming Early Detection of Cancer Conference brings together experts from multiple disciplines to share ground breaking research and progress in the field. Here...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...